Live feed08:00:00·52dPRReleasevia QuantisnowArcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic DermatitisByQuantisnow·Wall Street's wire, on your screen.ARQT· Arcutis Biotherapeutics Inc.Health Care
